WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
REDWOOD CITY, Calif., Feb. 15, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, February 29, 2016 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and year end 2015 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
Financial results will be released over the wire after market close on Monday, February 29, 2016 and posted at http://investors.coherus.com.
Conference Call Information
When: Monday, February 29, 2016 at 1:30 p.m. PT
Dial-in: (765) 507-2587 (domestic) or (844) 452-6826 (toll free)
Conference ID: 52921197
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
INVESTOR AND MEDIA CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
